Content about Atomoxetine

August 1, 2011

A federal court has upheld Eli Lilly's patent covering a drug used to treat attention deficit hyperactivity disorder, Lilly said Friday.

INDIANAPOLIS — A federal court has upheld Eli Lilly's patent covering a drug used to treat attention deficit hyperactivity disorder, Lilly said Friday.

Lilly said the U.S. Court of Appeals for the Federal Circuit overturned a ruling by the U.S. District Court for the District of New Jersey that had invalidated Lilly's patent for Strattera (atomoxetine) in a patent infringement case that Lilly had filed against generic drug maker Actavis, when the latter sought regulatory approval for a generic version of Strattera.

September 1, 2010

The Food and Drug Administration has approved a generic drug made by Actavis for treating...

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

 

The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

 

 

August 31, 2010

A generic drug maker has received regulatory approval for its version of an attention deficit...

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

August 12, 2010

The U.S. District Court for the District of New Jersey has ruled against drug maker...

INDIANAPOLIS The U.S. District Court for the District of New Jersey has ruled against drug maker Eli Lilly in its patent infringement case against generic drug maker Actavis regarding a drug used to treat attention deficit hyperactivity disorder, Lilly said.

 

The court ruled that a method-of-use patent covering the drug, Strattera (atomoxetine), was invalid. The patent was set to expire in May 2017.